Sort
30,917 grants matching “tumor microenvironment”
1/3 Morehouse School of Medicine/Tuskegee University/University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Partnership
$1,010,535Brian M. Rivers · Morehouse School Of Medicine · U54 · FY2024 · CA
Integrating targeted and immunotherapy to treat genetically heterogeneous cancers
$1,010,431William A Weiss · University Of California, San Francisco · U01 · FY2018 · CA
Integrating targeted and immunotherapy to treat genetically heterogeneous cancers
$1,010,431William A Weiss · University Of California, San Francisco · U01 · FY2020 · CA
Integrating targeted and immunotherapy to treat genetically heterogeneous cancers
$1,010,431William A Weiss · University Of California, San Francisco · U01 · FY2021 · CA
Nanosystems Biology Cancer Center
$1,009,425James R. Heath · California Institute Of Technology · U54 · FY2017 · CA
The power of extracellular vesicles in glioblastoma
$1,009,269Xandra Owens Breakefield · Massachusetts General Hospital · R35 · FY2021 · CA
The power of extracellular vesicles in glioblastoma
$1,009,233Xandra Owens Breakefield · Massachusetts General Hospital · R35 · FY2020 · CA
Exploring the Role of Nitrogen Metabolism in Cancer
$1,008,900Craig B Thompson · Sloan-Kettering Inst Can Research · R35 · FY2024 · CA
Towards targeting the lymphoma microenvironment
$1,008,898Hans-Guido Wendel · Sloan-Kettering Inst Can Research · R35 · FY2024 · CA
Preclinical Mouse Models for Studying Immune Checkpoint Inhibitor Response
$1,008,673Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Mechanism of action and therapeutic utility of stimulatory CpG oligonucleotides
$1,008,580Dennis Klinman · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Molecular, Cellular, and Tissue Characterization Unit
$1,008,368Dana Pe'er · Sloan-Kettering Inst Can Research · U2C · FY2021 · CA
Targeting intratumor heterogeneity in breast cancer
$1,007,771Kornelia Polyak · Dana-Farber Cancer Inst · R35 · FY2024 · CA
Mentoring Translational Researchers in Louisiana
$1,006,977Augusto C Ochoa · Lsu Health Sciences Center · P30 · FY2019 · GM
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States
$1,005,764Pablo Tamayo · University Of California, San Diego · U01 · FY2020 · CA
Systems analysis of mechanisms driving response to immunotherapy in clear cell cancers
$1,005,360Andrew J. Gentles · Stanford University · U01 · FY2025 · CA
Novel DNA Repair Inhibitors for Cancer Therapy
$1,005,000Peter M Glazer · Yale University · R35 · FY2018 · CA
Novel DNA Repair Inhibitors for Cancer Therapy
$1,004,921Peter M Glazer · Yale University · R35 · FY2020 · CA
Novel DNA Repair Inhibitors for Cancer Therapy
$1,004,920Peter M Glazer · Yale University · R35 · FY2021 · CA
Molecular pathways and targeted therapies in human leukemia
$1,004,909Adolfo A. Ferrando · Columbia University Health Sciences · R35 · FY2020 · CA
3D Spatial Multi-Omics Profiling of Ovarian Cancer
$1,004,570Samuel C Mok · University Of Tx Md Anderson Can Ctr · U01 · FY2024 · CA
INSIDE-OUT IMMUNOTHERAPY: PREVENTING METASTATIC BREAST CANCER RECURRENCE VIA NANOPARTICLE-DIRECTED MODULATION OF THE TUMOR MICROENVIRONMENT
$1,004,565Vanderbilt University · · FY2016 · Department of the Army
Precision microRNA medicine in cancer
$1,004,531Frank J. Slack · Beth Israel Deaconess Medical Center · R35 · FY2023 · CA
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting
$1,004,241Song Yao · Roswell Park Cancer Institute Corp · UG3 · FY2022 · CA
Biostatistics Core Resource
$1,004,179Susan G. Groshen · University Of Southern California · P30 · FY2009 · CA